Monolithic Power Systems Inc vs BIO-TECHNE Corp — how do they compare? Monolithic Power Systems Inc trades at $1,403.23 (market cap $67.87B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Monolithic Power Systems Inc is far larger — about 6× BIO-TECHNE Corp's market cap, and Monolithic Power Systems Inc pays the higher dividend (0.58%). Which is the better fit depends on your goals.
| MPWR | TECH | |
|---|---|---|
Market Cap | $67.87B | $11.24B |
Sector | Utilities | Health |
52-Week High | $1.69K | $72.29 |
52-Week Low | $797.51 | $43.31 |
Enterprise Value | $66.48B | $11.32B |
Dividend Yield | 0.58% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Monolithic Power Systems (MPWR) trades at $1,401.54, up 3.12% today, reflecting strong momentum after recent earnings beats. The stock exhibits a bullish technical trend, supported by robust fundamentals including 24.5% net income margin and 21.98% ROE. Recent Q2 2026 results showed EPS of $6.50, exceeding estimates, with revenue growth driven by AI infrastructure demand. Analyst sentiment remains overwhelmingly positive with 88% buy ratings.
The outlook for MPWR is favorable due to accelerating AI-driven revenue and expanding margins, though high valuation multiples (P/E 84.26) pose a risk if growth slows. Investor optimism is tempered by potential overvaluation and sensitivity to tech sector volatility. The consensus price target of $1,870 suggests upside, but execution risks and competitive pressures warrant caution.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Trailing returns across standard periods
Latest headlines on both assets
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →